Biomarkers In Seizure To Predict Recurrence and Severe Outcomes

NCT01774500 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2014-03-27

No results posted yet for this study

Summary

We study the hypothesis that combination of Proteine S100 beta and Copeptin within normal ranges can rule out seizure recurrences and severe outcome, and allow early discharge from the emergency department

Conditions

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    collaborator OTHER
  • Barts & The London NHS Trust

    collaborator OTHER
  • Bistro Study Group

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-01-31
Completion
2014-03-31

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01774500 on ClinicalTrials.gov